Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
OpenAI Rejects Apple Trade Secret Theft Claims 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Add as a preferred source on Google
DURHAM, N.C., March 07, 2018 -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present at the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018 at 8:00 a.m. ET at the Boston Marriott Copley Place.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology and compound library have produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and a new clinical candidate, CMX521, the first direct-acting antiviral specifically for the treatment and prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT:
Investor Relations:
Michelle LaSpaluto
(919) 972-7115
[email protected]
or
Will O’Connor
Stern Investor Relations
[email protected]
212-362-1200
Media:
Becky Vonsiatsky
W2O Group
[email protected]
413-478-2003
